Philadelphia, Pa. (April 2, 2013) – Persistent breast enlargement (gynecomastia) negatively affects self-esteem and other areas of mental and emotional health in adolescent males, reports the April issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).

Even mild gynecomastia can have adverse psychological effects in boys, according to the study by ASPS Member Surgeon Dr. Brian I. Labow and colleagues of Boston Children’s Hospital. They believe their findings have important implications for early intervention and treatment, including male breast reduction in appropriate cases.

Study Shows Psychological Impact of Gynecomastia in Boys

The researchers administered a series of psychological tests to 47 healthy boys, average age 16.5 years, being evaluated for gynecomastia. The results were compared to those of a group of boys without breast enlargement.

Sixty-two percent of the gynecomastia patients had mild to moderate breast enlargement. As in previous studies, many of the boys with gynecomastia were overweight or obese: 64 percent, compared to 41 percent of the comparison group.

Patients with gynecomastia had lower scores on a standard quality of life assessment, indicating problems in several areas. Even after adjustment for weight and body mass index (BMI), the patients had lower scores for general health, social functioning and mental health. They also had lower scores for physical health, but this was attributed to being overweight.

Breast enlargement was also associated with lower scores for self-esteem. This, along with impairment in emotional areas of quality of life, appeared directly related to gynecomastia, rather than being overweight.

Boys with gynecomastia also scored higher on a test of attitudes toward food and eating. However, there was no difference in the rate of clinical eating disorders between groups.

Psychosocial Effects Independent of Gynecomastia Severity

The negative psychological effects of gynecomastia were similar for boys at different levels of severity. “Merely having gynecomastia was sufficient to cause significant deficits in general health, social functioning, mental health, self-esteem, and eating behaviors and attitudes compared with controls,” Dr. Labow and coauthors write.

Gynecomastia is benign enlargement of male glandular tissue that is very common in adolescent boys. Although breast enlargement usually resolves over time, the problem persists in about eight percent of boys. Typically, boys with gynecomastia who are overweight or obese may simply be advised to lose weight.

However, losing weight won’t correct the problem in patients who have true glandular enlargement, or in those with a large amount of excess skin in the breast area. As shown by the new study, patients with gynecomastia may experience emotional and self-esteem issues regardless of body weight or the severity of breast enlargement.

“As a result, early intervention and treatment for gynecomastia may be necessary to improve the negative physical and emotional symptoms,” Dr. Labow and coauthors state. They note that male breast reduction, performed by a qualified plastic surgeon, is typically a simple and safe procedure.

It may seem self-evident that breast enlargement could have a psychological and emotional impact on teenage boys. However, adolescent gynecomastia has historically been regarded as a “cosmetic” procedure, not reimbursed by most insurance plans. The researchers note that only 35 percent of adolescent boys undergoing surgery for gynecomastia at their hospital were covered by insurance, compared to 85 percent of girls undergoing breast reduction.

“Our results indicate that careful and regular evaluation for gynecomastia may benefit adolescents regardless of BMI status or severity of gynecomastia,” Dr. Labow and colleagues conclude. They call for further studies to evaluate the effects of male breast reduction, including its impact on physical and psychological symptoms.

Plastic and Reconstructive Surgery® is published by Lippincott Williams & Wilkins, part of Wolters Kluwer Health.

About Plastic and Reconstructive Surgery

For more than 60 years, Plastic and Reconstructive Surgery® (http://journals.lww.com/plasreconsurg/) has been the one consistently excellent reference for every specialist who uses plastic surgery techniques or works in conjunction with a plastic surgeon. The official journal of the American Society of Plastic Surgeons, Plastic and Reconstructive Surgery® brings subscribers up-to-the-minute reports on the latest techniques and follow-up for all areas of plastic and reconstructive surgery, including breast reconstruction, experimental studies, maxillofacial reconstruction, hand and microsurgery, burn repair, and cosmetic surgery, as well as news on medico-legal issues.

About ASPS

The American Society of Plastic Surgeons (ASPS) is the world’s largest organization of board-certified plastic surgeons. Representing more than 7,000 Member Surgeons, the Society is recognized as a leading authority and information source on aesthetic and reconstructive plastic surgery. ASPS comprises more than 94 percent of all board-certified plastic surgeons in the United States. Founded in 1931, the Society represents physicians certified by The American Board of Plastic Surgery or The Royal College of Physicians and Surgeons of Canada. ASPS advances quality care to plastic surgery patients by encouraging high standards of training, ethics, physician practice and research in plastic surgery. You can learn more and visit the American Society of Plastic Surgeons at www.plasticsurgery.org or www.facebook.com/PlasticSurgeryASPS and www.twitter.com/ASPS_news.

About Lippincott Williams & WilkinsLippincott Williams & Wilkins (LWW) is a leading international publisher of trusted content delivered in innovative ways to practitioners, professionals and students to learn new skills, stay current on their practice, and make important decisions to improve patient care and clinical outcomes.

LWW is part of Wolters Kluwer Health, a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company with 2012 annual revenues of €3.6 billion ($4.6 billion).

Contacts:

Robert Dekker
Director of Communications
Wolters Kluwer Health
+1 (215) 521-8928
Robert.Dekker@wolterskluwer.com

Connie Hughes
Director, Marketing Communications
Wolters Kluwer Health Medical Research
+1 (646) 674-6348
Connie.Hughes@wolterskluwer.com

Philadelphia, Pa. (March 18, 2013) – Abuse of the anesthesia drug propofol is a “rapidly progressive form of substance dependence” that is being more commonly seen among health care professionals, reports a study in the April Journal of Addiction Medicine, the official journal of the American Society of Addiction Medicine.  The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

“Propofol addiction is a virulent and debilitating form of substance dependence” with a “rapid downhill course,” write Drs Paul Earley and Torin Finver of Georgia Health Professionals Program, Inc, Atlanta.  Their study identifies some emerging characteristics and consequences of propofol abuse among health care professionals.

Propofol Abuse:  Rates and Risk Factors

Data from an addiction center specializing in substance abuse problems among health care professionals identified 22 patients treated for propofol abuse from 1990 to 2010.  Propofol is a drug widely used to induce anesthesia for surgery and sedation for other procedures.  It is commonly used because it has a rapid onset and quick recovery time, with fewer side effects than other anesthetics.

The number of health care professionals treated for propofol abuse increased steadily during the period studied, although increased recognition by addiction center staff may have played a role.  The patients were thirteen physicians, eight nurses, and one dentist.  Most of the physicians and all of the nurses were anesthesia providers, who had ready access to propofol.

Patients using propofol were more likely to be women, compared to health care professionals abusing alcohol or other drugs.  Most propofol abusers had depression, along with a history of childhood sexual or physical abuse.  In addition, most of the propofol-abusing health care professionals reported a family history of substance abuse, and a higher than expected number had family members with schizophrenia.

The patients generally started using propofol to get to sleep.  However, they quickly developed characteristics of addiction, with propofol becoming a preferred drug of abuse.  Most patients came for addiction treatment within a few months after starting to use propofol.  Five patients came to treatment after a single propofol binge.

Side Effects of Propofol Abuse ‘Begin Almost Immediately’

“When humans abuse propofol, unintended side effects begin almost immediately,” Drs Earley and Finver write.  About half of propofol abusers entered addiction treatment after dramatic events such as car crashes or other injuries.  Some sustained facial injuries when they passed out immediately after injecting propofol.

Five patients were admitted into treatment when they were discovered unconscious.  These characteristics reflect the “narrow window between desired effect and unconsciousness” and the rapid loss of control over propofol use, according to the authors.

“Propofol dependence is a rapidly progressive form of substance dependence seen in 1.6 percent of all health care addiction cases reporting to treatment,” Drs Earley and Finver conclude.  Within the limitations of the data, the study suggests that propofol abuse by health care professionals is increasing—particularly among physician and nurse anesthesia providers with ready access to anesthetics.

Some characteristics of the patients studied—including their history of depression and childhood trauma and patterns of physical injury—have important implications for identification and treatment of propofol abuse by health care professionals.  Drs Earley and Finver add, “Outcome studies…are needed to help solve the difficult decisions of when and if a propofol-abusing health care professional should return to their high-risk work environment.”

About Journal of Addiction Medicine

The mission of Journal of Addiction Medicine, the official journal of the American Society of Addiction Medicine, is to promote excellence in the practice of addiction medicine and in clinical research as well as to support Addiction Medicine as a mainstream medical specialty.  Published bi-monthly, the Journal is designed for all physicians and other mental health professionals who need to keep up-to-date with the treatment of addiction disorders. Under the guidance of an esteemed Editorial Board, peer-reviewed articles published in the Journal focus on developments in addiction medicine as well as on treatment innovations and ethical, economic, forensic, and social topics,

About the American Society of Addiction Medicine

The American Society for Addiction Medicine is a professional society representing over 3,000 physicians dedicated to increasing access and improving quality of addiction treatment, educating physicians and the public, supporting research and prevention, and promoting the appropriate role of physicians in the care of patients with addictions.

About Lippincott Williams & Wilkins

Lippincott Williams & Wilkins (LWW) is a leading international publisher of trusted content delivered in innovative ways to practitioners, professionals and students to learn new skills, stay current on their practice, and make important decisions to improve patient care and clinical outcomes.

LWW is part of Wolters Kluwer Health, a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company with 2012 annual revenues of €3.6 billion ($4.6 billion).

Contacts:

Robert Dekker
Director of Communications
Wolters Kluwer Health
+1 (215) 521-8928
Robert.Dekker@wolterskluwer.com

Connie Hughes
Director, Marketing Communications
Wolters Kluwer Health Medical Research
+1 (646) 674-6348
Connie.Hughes@wolterskluwer.com

Philadelphia, Pa. (March 11, 2013) – Members of the Deaf community who suffer from mental health problems need culturally sensitive treatment to avoid misdiagnosis and inappropriate treatment, according to a report in the March Journal of Psychiatric Practice.  The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

“Deaf individuals comprise a cultural and linguistic minority group within the United States, and culturally and linguistically appropriate psychiatric treatment must reflect these differences,” according to Sarah A. Landsberger, PhD, and coauthors of the Indiana University School of Medicine, Indianapolis.  With the goal of providing guidance for hearing psychiatrists, the authors review the limited research literature on mental health care for deaf patients.

Providing Mental Health Care for Deaf Patients—Interpreters Needed!

Approximately 1.2 million American are functionally deaf―that is, they are unable to understand vocal communication even with hearing aids. Many deaf individuals identify culturally with the Deaf community and culture, in which deafness is not viewed as an impairment but rather as a locus of pride and identity.

When deaf patients require mental health services, the first major challenge is finding a means to communicate with the patient in order to elicit symptoms. Many deaf individuals use American Sign Language (ASL)—a manual language with its own grammar, syntax, and vocabulary.

“Ideally, clinicians most suited to working with the Deaf population are those who are fluent in ASL, have had significant exposure to the Deaf community, and understand Deaf cultural values,” Dr Landsberger and coauthors write.

Unfortunately, few providers meet these criteria.

For patients who are fluent in ASL, nonsigning clinicians will need to employ a certified interpreter with specialized training in mental health interpretation.  Finding such interpreters can be difficult, however.  Dr Landsberger and colleagues call for specialized mental health training for ASL interpreters who work in psychiatric settings.

Challenges in Communication, Diagnosis and Treatment

Unfortunately, some deaf individuals have never had adequate exposure to or training in ASL or other communication systems used by the Deaf population.  They may have serious language deficits, communicating mainly by gestures and mime. For these patients, the doctor may need to employ both a certified deaf interpreter—who is trained to help gather the intended message and put it into grammatically correct ASL—as well as an ASL interpreter.

Correct diagnosis is another challenge.  Evaluating for psychotic disorders, such as schizophrenia, in deaf patients can be especially difficult. A key question is whether the person has experienced hallucinations—especially auditory hallucinations (hearing voices). But how does one explain the concept of hearing voices to someone who has been deaf from birth?

Another common symptom of psychosis is disorganized thoughts, which are usually diagnosed based on disorganized speech.  Psychiatrists evaluating deaf patients need to be cautious to avoid misinterpreting language deficits as a symptom of psychosis.

Effectively providing “talk” therapy—that is, different types of psychotherapy—to deaf patients poses obvious challenges. The authors discuss ways of adapting psychotherapy to be more effective for deaf patients and how the presence of an interpreter may affect the doctor-patient therapeutic relationship.

“As with any cultural minority, providers should seek specific training and education to become culturally competent providers to deaf people,” Dr Landsberger and coauthors write.  “At a minimum, clinicians who have large numbers of deaf patients in their caseloads should be knowledgeable about Deaf culture and become fluent in sign language.”  They conclude by calling for more research concerning mental health care for the deaf.

About Journal of Psychiatric Practice

Journal of Psychiatric Practice®, a peer reviewed journal, publishes reports on new research, clinically applicable reviews, articles on treatment advances, and case studies, with the goal of providing practical and informative guidance for clinicians. Mental health professionals will want access to this journal­—for sharpening their clinical skills, discovering the best in treatment, and navigating this rapidly changing field. John M. Oldham, MD, is the editor in chief and past president of the American Psychiatric Association.

About Lippincott Williams & Wilkins

Lippincott Williams & Wilkins (LWW) is a leading international publisher of trusted content delivered in innovative ways to practitioners, professionals and students to learn new skills, stay current on their practice, and make important decisions to improve patient care and clinical outcomes.

LWW is part of Wolters Kluwer Health, a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company with 2012 annual revenues of €3.6 billion ($4.6 billion).

Contacts:

Robert Dekker
Director of Communications
Wolters Kluwer Health
+1 (215) 521-8928
Robert.Dekker@wolterskluwer.com

Connie Hughes
Director, Marketing Communications
Wolters Kluwer Health Medical Research
+1 (646) 674-6348
Connie.Hughes@wolterskluwer.com

“It is an honor to have been named publisher for Harvard Review of Psychiatry, recognized by psychiatrists as one of the most influential journals in their specialty,” commented Jayne Marks, Vice President Publishing at Wolters Kluwer Health Medical Research.  “We look forward to a productive partnership that will help the journal expand its reach and impact globally, with new digital publishing solutions and strategies.”

An early priority in the partnership will be the development of a Harvard Review of Psychiatry iPad® edition as well as an updated of journal’s website to support an enhanced content and digital strategy. The peer-reviewed journal will continue on a bimonthly publication schedule. 

The new partnership comes as Harvard Review of Psychiatry embarks on its third decade of publication. “We are very excited to have Wolters Kluwer Health – LWW as the new publishing partner for the Harvard Review of Psychiatry, said Editor-in-Chief Shelly F. Greenfield, MD, MPH. “We believe that LWW offers the resources to allow readers greater access to the journal, to provide continuing education credits for many of our articles, and to reach a global audience. We look forward to continuing our tradition of bringing high high-quality reviews of critical contemporary issues in psychiatry to an even wider audience in our new partnership with LWW.”

The Harvard Review of Psychiatry presents authoritative reviews and perspective pieces on timely topics in contemporary psychiatry, authored by experts from the Harvard Departments of Psychiatry and other leading institutions. Other features include a Clinical Challenge section, with a case presentation followed by discussion and debate from a panel of experts.

About the Harvard Review Of Psychiatry

The Harvard Review of Psychiatry is the authoritative source for scholarly reviews and perspectives on a diverse range of important topics in psychiatry. Founded by the Harvard Medical School Department of Psychiatry, the journal is peer-reviewed and not industry sponsored. It is the property of Harvard University and is affiliated with all of the Departments of Psychiatry at the Harvard teaching hospitals. 

Articles encompass all major issues in contemporary psychiatry, including (but not limited to) neuroscience, psychopharmacology, psychotherapy, history of psychiatry, and ethics.

About Lippincott Williams & Wilkins and Wolters Kluwer Health
Lippincott Williams & Wilkins (LWW) is a leading international publisher of trusted content delivered in innovative ways to practitioners, professionals and students to learn new skills, stay current on their practice, and make important decisions to improve patient care and clinical outcomes. LWW is part of Wolters Kluwer Health, a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company with 2011 annual revenues of €3.4 billion ($4.7 billion).

Philadelphia, Pa. (August 30, 2012) – A “contingency management” approach—offering incentives for negative drug tests—can help promote drug abstinence among pregnant women with heroin or cocaine addiction, reports a study in the September Addictive Disorders & Their Treatment.  The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

Contingency management (CM) works just as well whether the incentives are increased (escalating) or fixed over time, the study finds.  Incentives may also be useful in promoting other healthy behaviors during pregnancy, such as quitting smoking.  “These results further the scientific knowledge regarding CM treatment in opioid-dependent pregnant women by supporting the finding that the escalating and fixed CM schedules produce similar amounts of drug negatives urine samples early in treatment,” according to the new research by Hendrée E. Jones, PhD, and colleagues of The Johns Hopkins University School of Medicine, Baltimore.

Whether Fixed or Increasing, Incentives Promote Drug Abstinence

The researchers evaluated two approaches to contingency management in pregnant women being treated for addiction to opioids (heroin and related drugs) or cocaine.  Especially combined with poverty and mental health issues, cocaine and/or heroin abuse during pregnancy can lead to adverse health outcomes for both mother and child.

The study included 90 opioid-addicted women being treated at the Center for Addiction and Pregnancy in Baltimore.  Two-thirds of the women were randomly assigned to contingency management.  In the contingency management approach, patients receive incentives in the form of vouchers as a “reward” for achieving desired outcomes—in this case, negative urine tests showing abstinence from drugs.

One group received escalating incentives, with increasing rewards for each negative urine test.  The other group received fixed incentives—the same reward for each negative test.  Previous research has shown that incentives can quickly increase rates of targeted behavior in patients with substance abuse problems.

The vouchers could be exchanged for merchandise or gift certificates.  In the escalating group, the vouchers had a starting value of $7.50, which increased by $1 per sample day (MWF) as long as the tests remained negative.  In the fixed group, the vouchers were worth $25 for each negative urine test.

Both incentive programs continued for thirteen weeks.  All women received other standard counseling and treatment, including methadone replacement therapy for heroin addiction.

All measures of opioid and heroin dependence were similar in the two contingency management groups.  With 14 opportunities to provide urine samples, the average number of negative test results was 8.1 in the escalating incentive group and 7.4 in the fixed incentive group.

There was a tendency toward higher cocaine abstinence rates among women receiving escalating incentives.  However, after five weeks there was no significant difference between groups.

Added to previous studies, the new results strengthen the evidence that providing incentives for staying drug-free is a useful part of the treatment strategy for pregnant women with opioid dependency.  The researchers believe contingency management may be especially valuable in pregnant women—to quickly reduce drug exposure to the developing fetus, and to help in meeting the goal of having both the mother and baby be drug-free at delivery.

Other reports have suggested promising effects of incentive programs in reducing smoking among pregnant women with substance use disorders.  “One recent study found that voucher reinforcement for smoking reductions  during pregnancy had a significant impact on the  smoking reduction and abstinence rates in this vulnerable population,” comments coauthor Michelle Tuten, LCSW-C.  “These interventions appear to have a clinically meaningful impact on birth outcomes as well, although larger studies are needed to more fully explore birth outcome differences.”  Professor Tuten is conducting further research on contingency management to reduce exposure to maternal smoking.

For her work in developing behavioral and drug treatments for substance abuse in pregnant and parenting women, Dr Jones has been selected to receive the 2012 Association for Medical Education and Research in Substance Abuse (AMERSA) Betty Ford Award.  The award will be presented during this year’s AMERSA national conference on November 1 in Bethesda, Md., where Dr Jones will discuss new research affecting the clinical management of opioid dependence during pregnancy.

About Addictive Disorders & Their Treatment

Addictive Disorders & Their Treatment is a quarterly international journal devoted to practical clinical research and treatment issues related to the misuses of alcohol and licit and illicit drugs and the study and treatment of addictive disorders and their behaviors. The journal publishes broad-spectrum, patient-oriented coverage of all aspects of addiction, directed toward an audience of psychiatrists, clinical psychologists, psychopharmacologists, and primary care practitioners

About Lippincott Williams & Wilkins

Lippincott Williams & Wilkins (LWW) is a leading international publisher of trusted content delivered in innovative ways to practitioners, professionals and students to learn new skills, stay current on their practice, and make important decisions to improve patient care and clinical outcomes. LWW is part of Wolters Kluwer Health, a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company with 2011 annual revenues of €3.4 billion ($4.7 billion).

Contacts:

Robert Dekker
Director of Communications
Wolters Kluwer Health
+1 (215) 521-8928
Robert.Dekker@wolterskluwer.com

Connie Hughes
Director, Marketing Communications
Wolters Kluwer Health Medical Research
+1 (646) 674-6348
Connie.Hughes@wolterskluwer.com

Philadelphia, Pa. (July 11, 2012) – Specific types of “mindfulness practices” including Zen meditation have research-proven benefits for patients with certain physical and mental health problems, according to a report in the July Journal of Psychiatric Practice.  The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

“An extensive review of therapies that include meditation as a key component—referred to as mindfulness-based practices—shows convincing evidence that such interventions are effective in the treatment of psychiatric symptoms and pain, when used in combination with more conventional therapies,” according to Dr William R. Marchand of the George E. Wahlen Veterans Affairs Medical Center and the University of Utah in Salt Lake City.

Mindfulness Techniques Show Health Benefits

Dr Marchand reviewed published studies evaluating the health benefits of mindfulness-based practices.  Mindfulness has been described as “the practice of learning to focus attention on moment-by-moment experience with an attitude of curiosity, openness, and acceptance.”  Put another way, “Practicing mindfulness is simply experiencing the present moment, without trying to change anything.”

The review focused on three techniques:

• Zen meditation, a Buddhist spiritual practice that involves the practice of developing mindfulness by meditation, typically focusing on awareness of breathing patterns.
• Mindfulness-based stress reduction (MBSR), a secular method of using Buddhist mindfulness, combining meditation with elements of yoga and education about stress and coping strategies.
• Mindfulness-based cognitive therapy (MBCT), which combines MBSR with principles of cognitive therapy (for example, recognizing and disengaging from negative thoughts) to prevent relapse of depression.

Dr Marchand found evidence that MBSR and MBCT have “broad-spectrum” effects against depression and anxiety and can also decrease general psychological distress.  Based on the evidence, MBCT can be “strongly recommended” as an addition to conventional treatments (adjunctive treatment) for unipolar depression.  Both MBSR and MBCT were effective adjunctive treatments for anxiety.

Research data also supported the effectiveness of MBSR to help reduce stress and promote general psychological health in patients with various medical and/or psychiatric illnesses.   On its own, MBSR was helpful in managing stress and promoting general psychological health in healthy people.  There was also evidence that Zen meditation and MBSR were useful adjunctive treatments for pain management. 

How do these practices work to affect mental and physical health?  Dr Marchand discusses recent research showing the impact of mindfulness practices on brain function and structure, which may in part account for their psychological benefits.  “These mindfulness practices show considerable promise and the available evidence indicates their use is currently warranted in a variety of clinical situations,” he concludes.

The article includes some proposed evidence-based guidelines for incorporating mindfulness-based practices into health care.  So far there’s little evidence on which patients are most likely to benefit, but Dr Marchand suggests that patient preferences and enthusiasm are a good guide.  He comments, “The most important considerations may be desire to try a mindfulness-based practice and willingness to engage in the regular practice of seated meditation.”

About Journal of Psychiatric Practice

Journal of Psychiatric Practice® seizes the day with its emphasis on the three Rs—readability, reliability, and relevance. Featuring an eye-catching style, the journal combines clinically applicable reviews, case studies, and articles on treatment advances with practical and informative tips for treating patients.  Mental health professionals will want access to this review journal­—for sharpening their clinical skills, discovering the best in treatment, and navigating this rapidly changing field.  Journal of Psychiatric Practice combines clinically applicable reviews, case studies, and articles on treatment advances with informative “how to” tips for surviving in a managed care environment

About Lippincott Williams & Wilkins

Lippincott Williams & Wilkins (LWW) is a leading international publisher of trusted content delivered in innovative ways to practitioners, professionals and students to learn new skills, stay current on their practice, and make important decisions to improve patient care and clinical outcomes. LWW is part of Wolters Kluwer Health, a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company with 2011 annual revenues of €3.4 billion ($4.7 billion).

Contacts:

Robert Dekker
Director of Communications
Wolters Kluwer Health
+1 (215) 521-8928
Robert.Dekker@wolterskluwer.com

Connie Hughes
Director, Marketing Communications
Wolters Kluwer Health Medical Research
+1 (646) 674-6348
Connie.Hughes@wolterskluwer.com